CD8A and neoplasm: Taken together, these reports demonstrate that Th17 cells participate in antitumor immunity by facilitating T cell recruitment to the tumor site and CD8+ T cell priming and suggest a new avenue for developing Th17 cell-based therapy for lung cancer.